RE:RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsAn unmet need exists in pre-treated metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, which is a highly aggressive form of cancer.
In ONCY's Bracelet-1 study - pelareorep demonstrated that it was effective as a monotherapy when combined with paclitaxel versus paclitaxel alone.
https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-that-show-pelareorep-driving-robust-increases-in-progression-free-survival-and-confirm/